CytoDyn Files Request With FDA for Priority Review of BLA for First Approval
If granted, the FDA is expected to take action on the Company’s BLA within six months VANCOUVER, Washington, June 01,
Read more
cydy
CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir
VANCOUVER, Washington, May 18, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020
CytoDyn Submits Requested Datasets to FDA for Biologics License Application VANCOUVER, Washington, May 13, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:
Read more
FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S.
VANCOUVER, Washington, May 04, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries
54 eINDs approved by FDA and 49 patients have been treated with leronlimab thus far VANCOUVER, Washington, April 30, 2020
Read more
First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19
VANCOUVER, Washington, April 15, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7
VANCOUVER, Washington, April 09, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
Severely Ill COVID-19 Patient at Leading Southern California Medical Center Extubated Three Days After Treatment with CytoDyn’s Leronlimab; Two Moderate COVID-19 Patients Removed from External Oxygen Following One Day of Treatment with Leronlimab
VANCOUVER, Washington, April 09, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn’s Leronlimab
Novant Health operates a fully integrated healthcare system throughout four states VANCOUVER, Washington and WINSTON-SALEM, N.C., April 07, 2020 (GLOBE
Read more
“Next Super Stock” Conference Presenters Making News: CytoDyn (OTC: CYDY) New Coronavirus Treatment Progress. NexTech AR Solutions (OTC: NEXCF): Analyst Coverage; Remote Work/Learning Acquisition, Revenue Accelerates. FaceBank Group (OTC: FBNK) Completes Merger with Streamer fu-boTV ($223 million run rate).
NEW YORK, April 07, 2020 (GLOBE NEWSWIRE) — Wall Street Reporter, the trusted name in financial news since 1843, is
Read more
CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks
Recent data from China indicates mortality rate among COVID-19 patients requiring mechanical ventilator is more than 85% VANCOUVER, Washington, April
Read more
FDA Clears CytoDyn’s Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately
VANCOUVER, Washington, March 31, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more